Author
Memorial Sloan Kettering Cancer CenterORCID 0000-0002-8852-1120Unclaimed ORCID profile · follow to get notified of new preprints
4 papers
Recent·Most cited
Vera Tiedje, Jillian Greenberg, Tianyue Qin…·James A. Fagin
This study shows that loss of MHC Class II in BRAF-mutant anaplastic thyroid cancers leads to resistance to MAPK inhibitors by reducing CD4+ T-cell activation.
Gnana Prakasam Krishnamoorthy, Anthony Robert Glover, Brian R. Untch…·James A. Fagin
This study shows that RBM10 loss causes aberrant splicing of cytoskeletal and ECM genes, leading to RAC1 activation and metastatic fitness in thyroid cancer.
Vera Tiedje, Pablo Sánchez Vela, Julie L. Yang…·Ross L. Levine
This study identifies TET2-mutant clonal hematopoiesis in thyroid cancer microenvironments and shows that TGFβ signaling from these macrophages mediates resistance to BRAF/MEK inhibition, with TGFβ inhibition restoring sensitivity.
Kelly L. Bolton, Ryan N. Ptashkin, Teng Gao…·Elli Papaemmanuil
The paper shows oncologic therapy increases clonal hematopoiesis with DDR mutations, which predicts risk of therapy-related myeloid neoplasms.